Pharmacogenetics in Psychiatry: Are We Ready for Widespread Clinical Use?
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
There are high expectations about the capabilities of pharmacogenetics to tailor psychotropic treatment and "personalize" treatment. While a large number of associations, with generally small effect size, have been discovered, a "test" with widespread use and adoption is still missing. A more realistic picture, recognizing the important contribution of clinical and environmental factors toward overall clinical outcome has emerged. In this emerging view, genetic findings, if considered individually, may have limited clinical applications. Thus, in recent years, combinations of information in several genes have been used for the selection of appropriate therapeutic doses and for the prediction of agranulocytosis, hyperlipidemia, and response to antipsychotic and antidepressant medications. While these tests based on multiple genes show greater predictive ability than individual allele tests, their net impact on clinical consequence and costs is limited, thus leading to limited penetration into widespread clinical use. As one looks at other branches of medicine, there are successful examples of pharmacogenetic tests guiding treatment, and thus, it is reasonable to hope that with the incorporation of clinical and environmental information and the identification of new genes drawn from genome-wide analysis, will improve the predictive utility of these tests leading to their increased use by clinicians.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Interaction between BDNF and Serotonin: Role in Mood Disorders
Martinowich, K., & Lu, B. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301571 · Cited by 793 · cited 1×
“Loss of the brain-derived neurotrophic factor (BDNF) from the hippocampus contributes to vulnerability for depression, whereas BDNF upregulation mediates antidepressant efficacy.(108,109) Several recent reports have linked polymorphisms in the BDNF gene with response to antidepressant and antipsychotic drugs (OR: 2.”
BackgroundSerretti, A., Kato, M., De Ronchi, D., & Kinoshita, T. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001926 · Cited by 529
Adachi, M., Barrot, M., Autry, A. E., Theobald, D., & Monteggia, L. M. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.09.019 · Cited by 380
Smoking in Patients Receiving Psychotropic Medications: A Pharmacokinetic Perspective
Desai, H. D., Seabolt, J., & Jann, M. W. (2001) · CNS Drugs · doi:10.2165/00023210-200115060-00005 · Cited by 253
Substance use: a powerful predictor of relapse in schizophrenia
Swofford, C. D., Kasckow, J. W., Scheller-Gilkey, G., & Inderbitzin, L. B. (1996) · Schizophrenia Research · doi:10.1016/0920-9964(95)00068-2 · Cited by 247 · cited 1×
“Substance abuse is associated with poorer response and higher relapse rates.(13,14) Cigarette smoking induces CYP activity and accelerates the metabolism of substrate drugs.”
BackgroundThe effect of variable cigarette consumption on the interaction with clozapine and olanzapine
Haslemo, T., Eikeseth, P. H., Tanum, L., Molden, E., & Refsum, H. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0209-9 · Cited by 178
Predictors of Relapse in a Prospective Study of Fluoxetine Treatment of Major Depression
McGrath, P. J., Stewart, J. W., Quitkin, F. M., Chen, Y., Alpert, J. E., Nierenberg, A. A., Fava, M., Cheng, J., & Petkova, E. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1542 · Cited by 111
Attention-Deficit/Hyperactivity Disorder Pharmacogenomics
McGough, J. J. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.10.021 · Cited by 92
A score for predicting response to pharmacotherapy in obsessive???compulsive disorder
Denys, D., Burger, H., van Megen, H., de Geus, F., & Westenberg, H. (2003) · International Clinical Psychopharmacology · doi:10.1097/00004850-200311000-00002 · Cited by 68
Cited by
DeRubeis, R. J., Cohen, Z. D., Forand, N. R., Fournier, J. C., Gelfand, L. A., & Lorenzo-Luaces, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0083875 · Cited by 509
Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.025 · Cited by 385
New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis
Yang, A., & Tsai, S.-J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081689 · Cited by 282
WPA guidance on mental health and mental health care in migrants
BHUGRA, D., GUPTA, S., BHUI, K., CRAIG, T., DOGRA, N., INGLEBY, J. D., KIRKBRIDE, J., MOUSSAOUI, D., NAZROO, J., QURESHI, A., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00002.x · Cited by 244
Kambeitz, J., Romanos, M., & Ettinger, U. (2014) · The Pharmacogenomics Journal · doi:10.1038/tpj.2013.9 · Cited by 64
Metadata
- Authors
- Arranz, M. J., & Kapur, S.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-08-20
- Volume
- 34
- Issue
- 6
- Pages
- 1130-1144
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W2129656162
- Cited by
- 95
- References
- 10
- FWCI
- 12.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacogenetics in Psychiatry: Are We Ready for Widespread Clinical Use? https://app.cochat.ai/papers/10.1093/schbul/sbn114
- The paper
- Arranz, M. J., & Kapur, S. (2008). Pharmacogenetics in Psychiatry: Are We Ready for Widespread Clinical Use? Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbn114
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.